Article | February 29, 2024

Insights Into GMP Manufacturing Of RNA-LNP Drug Products

GettyImages-1087219020 Scientists wearing protective coveralls working in manufacturing laboratory

The advent of RNA-encapsulated lipid nanoparticles (LNPs) has brought about a seismic shift in pharmaceutical innovation. Yet, harnessing these cutting-edge platforms with a broad range of applications in therapeutic development demands strict adherence to manufacturing standards and adept navigation of complex regulatory frameworks. Compliance with Good Manufacturing Practice (GMP) regulations throughout the manufacturing process is crucial for mitigating risks, ensuring product consistency, and upholding patient safety.

Manufacturers must establish robust quality management systems that encompass comprehensive documentation, process controls, and analytics to ensure regulatory compliance and product quality. This necessitates adherence to validated manufacturing processes and thorough characterization of critical quality attributes (CQAs). Implementing a flexible manufacturing workflow that integrates advancements in production, automation, and advanced digital technologies plays a pivotal role in streamlining and optimizing GMP manufacturing processes for RNA-LNP drug products. Explore key considerations for GMP manufacturing including process and analytical development, automation, environmental monitoring, facility design, and strategic collaborations with technology providers.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene